問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2024-09-01 - 2029-05-25
Condition/Disease
Test Drug
Participate Sites4Sites
Recruiting4Sites
2025-11-15 - 2030-03-31
Participate Sites3Sites
Not yet recruiting3Sites
2024-09-01 - 2026-09-01
Not yet recruiting4Sites
2021-12-01 - 2025-06-30
Participate Sites5Sites
Recruiting5Sites
2025-02-20 - 2027-10-29
2023-07-01 - 2025-12-31
xxxxxx
Recruiting3Sites
2018-06-01 - 2024-12-31
Enterovirus 71 (EV71)
nactivated EV71 whole viral particles adjuvanted with aluminum (Al(OH)3)
Participate Sites7Sites
Terminated7Sites
2021-10-01 - 2027-12-31
Recruiting7Sites
2025-10-01 - 2028-12-31
第 1 部分：*評估在 pMMR/non-MSI-H 大腸直腸癌患者中，遞增劑量的 ABT-301 與固定劑量的 Tislelizumab（200 mg，靜脈輸注）和 Bevacizumab（7.5 mg/kg，靜脈輸注，每 3 週一次）合併使用時的安全性及耐受性。*確定 ABT-301 的最大耐受劑量 (MTD) 並選擇其建議的第二期劑量 (RP2D)。第 2 部分：*評估兩種劑量/方案的 ABT-301 與 Tislelizumab 和 Bevacizumab 合併使用的療效。
膠囊劑 靜脈輸注液 靜脈輸注液
2021-08-01 - 2026-03-31
全部
